May 17, 2020

Telemedicine Consultations and Wearable Tech Sales to Escalate in 2015

Telemedicine
hospital technology
wearable tech
United Sta
Admin
2 min
Connected trackers will account for 52 percent of all digital fitness tracker unit sales in 2014 and reach 81 percent by 2018.
The number of doctor-patient video consultations in the United States will almost triple over the next year, according to research from Parks Associates...

The number of doctor-patient video consultations in the United States will almost triple over the next year, according to research from Parks Associates. The firm expects the number of patients contacting a physician remotely by video to triple from 5.7 million in 2014 to more than 16 million next year.

“The connected health markets are experiencing tremendous growth both in end-user connected devices and on the institutional side,” said Harry Wang, director of Health & Mobile Product Research in an issued release.  

According to Parks, approximately 42 percent of households in the U.S. with broadband services had used at least one online service offered to them by their physicians. The most common use being online prescription refills.

Nearly 30 percent of said households also owned and used at least one connected health device.

The number of connected digital trackers sold worldwide will also double again in 2014 and top 22 million, according to Parks. The number sold in 2012 was 6.6 million and 13.6 million last year.

“Connected trackers will account for 52 percent of all digital fitness tracker unit sales in 2014 and reach 81 percent by 2018 (66 million units),” Wang said in a statement. “Smart watches are another wearables category poised for tremendous growth, with sales of almost 18 million units worldwide in 2014 and 121 million in 2018. These connected devices open new avenues for new fitness apps, health solutions and data analytics.”

Based on a survey of 10,000 households in the U.S. with broadband services during the first quarter of 2014, Parks predicted that only 2 percent of such households had bought a smart watch in 2013 and another 4 percent are likely to buy one over the course of the next 12 months.

Within that group of buyers, 20 percent bought their smart watch directly from the maker, 18 percent from Amazon and 17 percent from Best Buy. Almost half had received a smart watch as a gift. 

Share article

Jun 23, 2021

Introducing Dosis - the AI powered dosing platform

AI
medication
personalisedmedicine
chronicdisease
3 min
Dosis is an AI-powered personalised medication dosing platform that's on a mission to transform chronic disease management

Cloud-based platform Dosis uses AI to help patients and clinicians tailor their medication plans. Shivrat Chhabra, CEO and co-founder, tells us how it works. 

When and why was Dosis founded?
Divya, my co-founder and I founded Dosis in 2017 with the purpose of creating a personalised dosing platform. We see personalisation in so many aspects of our lives, but not in the amount of medication we receive. We came across some research at the University of Louisville that personalised the dosing of a class of drugs called ESAs that are used to treat chronic anaemia. We thought, if commercialised, this could greatly benefit the healthcare industry by introducing precision medicine to drug dosing. 

The research also showed that by taking this personalised approach, less drugs were needed to achieve the same or better outcomes. That meant that patients were exposed to less medication, so there was a lower likelihood of side effects. It also meant that the cost of care was reduced. 

What is the Strategic Anemia Advisor? 
Dosis’s flagship product, Strategic Anemia Advisor (SAA), personalises the dosing of Erythropoiesis Stimulating Agents (ESAs). ESAs are a class of drugs used to treat chronic anaemia, a common complication of chronic kidney disease. 

SAA takes into account a patient’s previous ESA doses and lab levels, determines the patient’s unique response to the drug and outputs an ESA dose recommendation to keep the patient within a specified therapeutic target range. Healthcare providers use SAA as a clinical decision support tool. 

What else is Dosis working on? 
In the near term, we are working on releasing a personalised dosing module for IV iron, another drug that’s used in tandem with ESAs to treat chronic anaemia. We’re also working on personalising the dosing for the three drugs used to treat Mineral Bone Disorder. We’re very excited to expand our platform to these new drugs. 

What are Dosis' strategic goals for the next 2-3 years? 
We strongly believe that personalised dosing will be the standard of care within the next decade, and we’re honored to be a part of making that future a reality. In the next few years, we see Dosis entering partnerships with other companies that operate within value-based care environments, where tools like ours that help reduce cost while maintaining or improving outcomes are extremely useful.

What do you think AI's greatest benefits to healthcare are?
If designed well, AI in healthcare allows for a practical and usable way to deploy solutions that would not be feasible otherwise. For example, it’s possible for someone to manually solve the mathematical equations necessary to personalise drug dosing, but it is just not practical. AI in healthcare offers an exciting path forward for implementing solutions that for so long have appeared impractical or impossible.

Share article